Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive

NCT07357727 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07357727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07357727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 3
Overall status
Recruiting
Start date
May 27, 2026
Completion date
December 27, 2030
Enrollment
460 (estimated)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

post-essential thrombocythemia myelofibrosis (pet-mf), post-polycythemia vera myelofibrosis (ppv-mf), primary myelofibrosis (pmf)